Alexandra Langlais nackt sorted by
relevance

Admin22.07.2021

Mesothelioma: Langlais, Alexandra

Langlais nackt Alexandra France: Langlais,
Although taxan-based therapy shows poorest PFS in first-line, no chemotherapy regimen was associated with prognosis.
poses
3007
Admin13.08.2021

Mesothelioma: Langlais, Alexandra

Langlais nackt Alexandra Mesothelioma: Langlais,
received personal fees from Astra Zeneca, Roche, Bristol—Myers Squibb, Takeda, Pfizer, Boehringer Ingelheim, and Novartis.
fake-tits
2901
Admin17.08.2021

France: Langlais, Alexandra

Langlais nackt Alexandra Mesothelioma: Langlais,
Among patients whose relative ctDNA abundance was below the median, those treated with atezolizumab tended to have higher OS than those in the chemotherapy arm.
public
1701
Admin27.07.2021

Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab

Langlais nackt Alexandra Mesothelioma: Langlais,
Patients harboring KRAS mutations plus another alteration had an OS time 13.
bodyparts
3406
Admin17.09.2021

Mesothelioma: Langlais, Alexandra

Langlais nackt Alexandra Circulating Tumor
14 Service de Pneumologie, 58 Rue Montalembert, CHU G Montpied, 63000 Clermont Ferrand, France.
shorts
51010
Admin31.07.2021

France: Langlais, Alexandra

Langlais nackt Alexandra France: Langlais,
Patients with detectable ctDNA had a significantly lower disease control rate at week 6 compared with patients with no detectable ctDNA, regardless of the nature of the treatment.
shorts
6702
Admin03.08.2021

Mesothelioma: Langlais, Alexandra

Langlais nackt Alexandra France: Langlais,
received personal fees from AbbVie, Bristol—Myers Squibb, Boehringer Ingelheim, Astra Zeneca, Roche, Novartis, MSD, Pfizer, and Takeda.
bottomless
3804
Admin26.06.2021

France: Langlais, Alexandra

Langlais nackt Alexandra France: Langlais,
RESULTS: We identified 162 patients 0.
milf
5806
Admin15.07.2021

Mesothelioma: Langlais, Alexandra

Langlais nackt Alexandra France: Langlais,
The purpose of the present study was to determine whether circulating tumor DNA ctDNA , prospectively collected at treatment initiation, was associated with the prognosis of SCLC, and whether it identified patients who benefited from atezolizumab.
office
3403
Admin06.07.2021

Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab

Langlais nackt Alexandra France: Langlais,
78 , and objective response rate under first-line chemotherapy 41.
one-piece
1900